This is a working overview of ghrelin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic pentapeptide | GHS-R1a agonist family |
| Receptor target | Ghrelin receptor (GHS-R1a) | G-protein-coupled receptor |
| Sequence length | Five amino acid residues | Includes non-natural residues |
| Primary reported output | Pulsatile growth hormone release | Observed in animal and early human work |
| Molecular formula | C38H49N9O5 | Corresponds to roughly 711.9 g/mol |
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
In amniotes, the clitoris ( KLIT-ər-iss or klih-TOR-iss; pl.: clitorises or clitorides) is a female sex organ. In humans, it is the vulva's most erogenous area and generally the primary anatomical source of female sexual pleasure. The clitoris is a complex structure, and its size and sensitivity can vary. The visible portion, the glans, of the clitoris is typically roughly the size and shape of a pea and is estimated to have more than 10,000 nerve endings. Sometimes in common speech, clitoris or clit is used to solely reference the glans. Sexological, medical, and psychological debate has focused on the clitoris, and it has been subject to social constructionist analyses and studies. Such discussions range from anatomical accuracy, gender inequality, female genital mutilation, and orgasmic factors and their physiological explanation for the G-spot. The only known purpose of the human clitoris is to provide sexual pleasure. Knowledge of the clitoris is significantly affected by its cultural perceptions. Studies suggest that knowledge of its existence and anatomy is scant in comparison with that of other sexual organs (especially male sex organs) and that more education about it could help alleviate stigmas, such as the idea that the clitoris and vulva in general are visually unappealing or that female masturbation is taboo and disgraceful. The clitoris is homologous to the majority of the penis in males.
Multiple stages of mass analysis separation can be accomplished with individual mass spectrometer elements separated in space or using a single mass spectrometer with the MS steps separated in time. For tandem mass spectrometry in space, the different elements are often noted in a shorthand, giving the type of mass selector used.
On 28 February 2026, Israel and the United States launched an air war against Iran, killing its supreme leader and many other officials. Iran responded with missile and drone strikes against Israel, US bases, and US-allied countries in the Middle East, and by closing the Strait of Hormuz, disrupting global trade. US president Donald Trump wrote on 6 March 2026 that there will be no deal with Iran except its unconditional surrender. On 9 March, Trump said that "the war is very complete, pretty much", and claimed that the Iranian military had been destroyed and the Strait of Hormuz had re-opened. On 15 March he demanded that NATO and China help the US to re-open the strait. Trump again claimed on 24 March that the US and Israel had "won" the war, even though Iran continued its missile strikes. In late March, Trump repeatedly threatened to destroy Iran's infrastructure if it did not make a "deal" with the US and re-open the Hormuz strait. Trump said on 23 March that the US has been speaking to "a top person" in Iran and claimed "They called, I didn't call. They want to make a deal, and we are very willing to make a deal". The IRGC-affiliated Fars News denied there had been any negotiations with Trump. The Iranian foreign ministry said it was merely reviewing proposals from the US sent through mediators. On 25 March, Pakistani officials delivered a "15-point proposal" from the US to Iran, detailing a ceasefire plan.
Holmes and Balwani were also charged with wire fraud and conspiracy, with Holmes being found guilty on four counts in January 2022 and sentenced that November to 11 years and 3 months in prison. Balwani was convicted on all 12 counts brought against him in July 2022, and in December 2022 was sentenced to 12 years and 11 months in prison and 3 years of probation.
== External links == IUPAC's "Glossary of Terms Used in Combinatorial Chemistry" ACS Combinatorial Science (formerly Journal of Combinatorial Chemistry) Combinatorial Chemistry Review "Molecular Diversity". metapress.com. Archived from the original on May 15, 2016. Combinatorial Chemistry and High Throughput Screening Combinatorial Chemistry: an Online Journal SmiLib - A free open-source software for combinatorial library enumeration GLARE - A free open-source software for combinatorial library design
Sources: en.wikipedia.org
In CYP2D6 extensive metabolizers, the half-lives of 4-hydroxyatomoxetine and N-desmethylatomoxetine are similar at around 6 to 8 hours, whereas in CYP2D6 poor metabolizers, the half-life of N-desmethylatomoxetine is much longer at around 33 to 40 hours. Atomoxetine levels in cerebrospinal fluid (CSF) with atomoxetine at a dosage of 80 mg/day were 6.6 ng/mL at 8 hours post-dose and 1.4 ng/mL at 24 hours post-dose following 2 weeks of administration.
=== Spinal puncture === Following spinal anesthesia or puncture, people who are being treated with anti-thrombotic agents are at higher risk for developing a hematoma, which causes long-term or permanent paralysis. The risk of this may be increased by using epidural or intrathecal catheters after a surgical operation or from the concurrent use of medicinal agents that affect hemostasis.
== Development from 'Peptide 3' == 'Peptide 3' is a 12-amino acid linear peptide corresponding to amino acids 51 to 62 of mature human chemokine CCL2. It is formed from L-amino acids with the sequence NH2-Glu-Ile-Cys-Ala-Asp-Pro-Lys-Gln-Lys-Trp-Val-Gln-OH (or in single letter code NH2-EICADPKQKWVQ-OH). 'Peptide 3' was found to be a Broad-Spectrum Chemokine Inhibitor inhibiting chemotaxis of human myelomonocytic cell line THP-1 monocytes and human neutrophils induced by a range of chemokines including CCL2, CCL3, CXCL8 and CXCL12 with roughly equal potency of 10μM, but not migration induced by other non-chemokine chemoattractants such as n-formyl-Met-Leu-Phe (fMLP) or TGF-β. Biotinylated 'Peptide 3' was found to bind to THP-1 cells with a disassociation constant of roughly 10μM. This suggested that 'Peptide 3' functions as a chemokine receptor antagonist. This mechanism was later proved to not be in action.
=== Manufacture === Production of the Il-86 began in late 1976 and continued until 1991. There was no prototype. The first two machines were handmade by Ilyushin at the bureau's own Moscow facility in 1976 and 1977. One was used for flight testing and the other for static ground testing. Beyond these initial examples, Ministry of Aircraft Manufacture ("MAP," "Minaviaprom") Factory 64 at Voronezh (today VASO) was tasked with building more than half of each Il-86 and performing final assembly. Three aircraft were assembled at Voronezh by 1979. The first (flown on October 25, 1977) was built largely by hand, subsequent machines making increasing use of production equipment. These aircraft were used in certification and development flying before handover to Aeroflot. Voronezh factory production engineers conducted a "redesign cycle" of over 50 areas, cutting some 1,500 kg (3,300 lb) of airframe weight. Capacity at Voronezh was insufficient and the Polish aircraft industry was involved in the Il-86 project from the start. The arrangement involved significant technology transfer to Poland: PZL (Państwowe Zakłady Lotnicze) Amalgamation Mielec factory Director Jerzy Belczak said it involved “... a radical retooling of our enterprise” involving “over 50 new processes.” Observers noted that "work on the Il-86 will bring Poland's ... WSK-Mielec to a new level of capability ...
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.
Studies generally report growth hormone as the dominant output, with smaller or absent effects on adrenocorticotropic hormone and prolactin. The size of that separation depends on the assay and the dose examined, so it is best described as relative selectivity.
No natural source has been identified, and the molecule is produced by chemical synthesis. Its non-natural residues distinguish it from endogenous ghrelin even though both engage the same receptor.
Dry powder is held at minus twenty degrees Celsius or colder, away from light and moisture. Sealed vials under inert gas limit degradation during storage.